Determining how these risks manifest in AML patients, who may have other particular risk factors (e.g., anthracycline exposure; TET2-mutated clonal hematopoiesis), will mandate design of specific endpoints and exploratory research in future trials. The gene discussed is TET2; the disease is acute myeloid leukemia.